OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.

OBJECTIVES: OSKIRA-4 evaluated the efficacy of fostamatinib monotherapy versus placebo on the signs and symptoms of rheumatoid arthritis over 6 weeks by Disease Activity Score C reactive protein (DAS-28(CRP)) and assessed non-inferiority to adalimumab monotherapy at Week 24 by DAS-28(CRP). METHODS:...

Celý popis

Podrobná bibliografie
Hlavní autoři: Taylor, P, Genovese, M, Greenwood, M, Ho, M, Nasonov, E, Oemar, B, Stoilov, R, Vencovsky, J, Weinblatt, M
Médium: Journal article
Jazyk:English
Vydáno: 2014